Elevance Health (ELV) Goldman Sachs 45th Annual Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Goldman Sachs 45th Annual Global Healthcare Conference summary
3 Feb, 2026Financial performance and utilization trends
Guidance reaffirmed with stable utilization trends across Medicare, Medicaid, and commercial lines, consistent with Q1 and expectations for Q2.
Medicare shows stabilization in inpatient trends, with some ongoing outpatient increases in cardio, physical therapy, and radiology.
Medicaid trends are driven by acuity mix shifts due to redeterminations, not by per-member utilization increases.
Commercial business trends remain stable and accurately priced, supporting continued confidence in outlook.
Ongoing active discussions with states on Medicaid rates, with constructive progress and actuarially sound rates expected.
Strategic initiatives and care delivery
Recent partnership with CD&R, Apree Health, and MPG aligns with a capital-efficient, enablement-focused approach to value-based care.
The strategy leverages strengths across commercial, Medicare, and Medicaid, with scalable, payer-agnostic solutions.
Synergies expected through technology integration, EMR capabilities, and specialty enablement, with a long-term plan to bring assets in-house.
Growth will be accelerated by targeted provider engagement and capital for acquisitions, with deliberate application of Carelon services.
Expansion into risk-based and global capitation arrangements in primary care, with subcapitated specialty partnerships for complex care.
Medicare and commercial business strategy
Medicare bids for 2025 were approached with discipline, focusing on margin stability and local market competitiveness.
Recent years saw exits from unprofitable plans and benefit rationalization, with margin improvement and stable to improving outlook for 2025.
Commercial margins have returned to pre-pandemic levels, with incremental opportunities for further improvement and growth in fee-based business.
Integrated pharmacy-medical solutions are increasingly demanded, especially in large group RFPs.
Down-market employers remain paternalistic, with limited appetite for ICHRAs, but ACA competitiveness supports membership retention.
Latest events from Elevance Health
- 2025 saw double-digit revenue growth, robust ESG progress, and strong board and pay governance.ELV
Proxy filing27 Mar 2026 - Virtual annual meeting to vote on directors, pay, auditors, and a political contributions ESG proposal.ELV
Proxy filing27 Mar 2026 - 2026 guidance is cautious, but margin recovery and 12%+ EPS growth are targeted for 2027.ELV
Q4 20253 Feb 2026 - Q2 adjusted EPS up 12% to $10.12; Carelon growth and divestitures offset Medicaid declines.ELV
Q2 20243 Feb 2026 - Q3 2024 revenue up 5.3% to $44.7B; net income down 22.5% amid Medicaid cost pressures.ELV
Q3 202419 Jan 2026 - AI investments, M&A, and Carelon expansion drive growth amid Medicaid and MA margin pressures.ELV
UBS Global Healthcare Conference 202414 Jan 2026 - 2024 revenue up 3% to $175.2B; 2025 outlook sees higher EPS and strong capital returns.ELV
Q4 20249 Jan 2026 - Board proposals passed, diversity reporting failed, with strong financials and digital care focus.ELV
AGM 20256 Jan 2026 - Q1 2025 revenue up 15.4%, adjusted EPS up 10.5%, net income down 2.9%, guidance reaffirmed.ELV
Q1 202521 Dec 2025